{"transactions":[{"id":727426,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:34:58.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":2333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026."}],"balance_after":2333,"derivative":{"exercise_price":8.35,"expiration_date":"2036-06-22","underlying":"Common Stock","underlying_shares":2333},"source":{"system":"sec-edgar","filing":"0001580111-26-000010","document":"form4-06242026_100652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000010/form4-06242026_100652.xml","form_type":"4"}},{"id":771408,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-19T20:59:48.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":2169103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":2169103,"derivative":{"exercise_price":7.39,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":2169103},"source":{"system":"sec-edgar","filing":"0001580111-26-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000158011126000009/ownership.xml","form_type":"4"}},{"id":771407,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:59:48.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":553844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were acquired pursuant to a performance RSU (\"PRSU\") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration."}],"balance_after":1153962,"source":{"system":"sec-edgar","filing":"0001580111-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000158011126000009/ownership.xml","form_type":"4"}},{"id":771406,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:59:48.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":600118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":600118,"source":{"system":"sec-edgar","filing":"0001580111-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000158011126000009/ownership.xml","form_type":"4"}},{"id":788248,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T00:27:06.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates."}],"balance_after":56000,"derivative":{"exercise_price":9.63,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001580111-26-000007","document":"form4-05082026_120559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000007/form4-05082026_120559.xml","form_type":"4"}},{"id":801683,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the \"RSU Vesting Date\"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801682,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.01,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801681,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32335,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801680,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801679,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801678,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40300},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801677,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":801676,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T20:37:25.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57310,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001580111-26-000001","document":"form4-04232026_080421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011126000001/form4-04232026_080421.xml","form_type":"4"}},{"id":1004659,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":32335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":32335,"derivative":{"exercise_price":8.99,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004658,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.87,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004657,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":37500,"derivative":{"exercise_price":8.99,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004656,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.69,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004655,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":28700,"derivative":{"exercise_price":8.99,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004654,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16.29,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004653,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":40300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":40300,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40300},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004652,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40300},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004651,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":40000,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1004650,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:14:39.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001580111-25-000003","document":"form4-11072025_111135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000158011125000003/form4-11072025_111135.xml","form_type":"4"}},{"id":1066670,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-08-14T16:09:05.000Z","date":"2025-08-11","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-021825","document":"form4-08142025_080802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925021825/form4-08142025_080802.xml","form_type":"4"}},{"id":1066669,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option","published_at":"2025-08-14T16:09:05.000Z","date":"2025-08-11","kind":"other","planned":false,"acquired":false,"shares":998854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":998854},"source":{"system":"sec-edgar","filing":"0001415889-25-021825","document":"form4-08142025_080802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925021825/form4-08142025_080802.xml","form_type":"4"}},{"id":1066668,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-08-14T16:09:05.000Z","date":"2025-08-11","kind":"other","planned":false,"acquired":false,"shares":1218836,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021825","document":"form4-08142025_080802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925021825/form4-08142025_080802.xml","form_type":"4"}},{"id":1122408,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit (RSU)","published_at":"2025-06-04T21:47:51.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the \"RSU Vesting Date\"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an \"unforeseeable emergency,\" as that term is defined under the Issuer's deferred compensation plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-015620","document":"form4-06042025_090648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000141588925015620/form4-06042025_090648.xml","form_type":"4"}},{"id":1122407,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-06-04T21:47:51.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date."}],"balance_after":22500,"derivative":{"exercise_price":7.01,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001415889-25-015620","document":"form4-06042025_090648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000141588925015620/form4-06042025_090648.xml","form_type":"4"}},{"id":1300334,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-17T18:03:43.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-001719","document":"form4-01172025_110140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925001719/form4-01172025_110140.xml","form_type":"4"}},{"id":1300333,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-17T18:03:43.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date."}],"balance_after":400000,"derivative":{"exercise_price":6,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001415889-25-001719","document":"form4-01172025_110140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925001719/form4-01172025_110140.xml","form_type":"4"}},{"id":1499955,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2024-05-28T22:21:04.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":32335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":32335,"derivative":{"exercise_price":13.87,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001415889-24-014714","document":"form4-05282024_100500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000141588924014714/form4-05282024_100500.xml","form_type":"4"}},{"id":1520959,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-05-10T16:04:44.000Z","date":"2024-05-09","kind":"exercise","planned":true,"acquired":false,"shares":20222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":433854,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":20222},"source":{"system":"sec-edgar","filing":"0001415889-24-012841","document":"form4-05102024_080532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924012841/form4-05102024_080532.xml","form_type":"4"}},{"id":1520958,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-05-10T16:04:44.000Z","date":"2024-05-09","kind":"sale","planned":true,"acquired":false,"shares":20222,"price":12.1798,"value":246299.9156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1218836,"source":{"system":"sec-edgar","filing":"0001415889-24-012841","document":"form4-05102024_080532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924012841/form4-05102024_080532.xml","form_type":"4"}},{"id":1520957,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-05-10T16:04:44.000Z","date":"2024-05-09","kind":"exercise","planned":true,"acquired":true,"shares":20222,"price":4.2,"value":84932.4,"ownership":{"direct":true},"balance_after":1239058,"source":{"system":"sec-edgar","filing":"0001415889-24-012841","document":"form4-05102024_080532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924012841/form4-05102024_080532.xml","form_type":"4"}},{"id":1542019,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-04-15T16:14:15.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":false,"shares":13558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":454076,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":13558},"source":{"system":"sec-edgar","filing":"0001415889-24-010808","document":"form4-04152024_080410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924010808/form4-04152024_080410.xml","form_type":"4"}},{"id":1542018,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-15T16:14:15.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":13558,"price":12.1857,"value":165213.7206,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on [Month XX, 2023]."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1218836,"source":{"system":"sec-edgar","filing":"0001415889-24-010808","document":"form4-04152024_080410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924010808/form4-04152024_080410.xml","form_type":"4"}},{"id":1542017,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-15T16:14:15.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":true,"shares":13558,"price":4.2,"value":56943.6,"ownership":{"direct":true},"balance_after":1232394,"source":{"system":"sec-edgar","filing":"0001415889-24-010808","document":"form4-04152024_080410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924010808/form4-04152024_080410.xml","form_type":"4"}},{"id":1682957,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Option Grant (right to buy)","published_at":"2024-01-09T16:08:30.000Z","date":"2024-01-05","kind":"grant","planned":false,"acquired":true,"shares":396000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four-year period: 1/48th on February 5, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":396000,"derivative":{"exercise_price":10.89,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":396000},"source":{"system":"sec-edgar","filing":"0001209191-24-001236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919124001236/doc4.xml","form_type":"4"}},{"id":1685797,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Option Grant (right to buy)","published_at":"2024-01-05T17:14:04.000Z","date":"2024-01-05","kind":"grant","planned":false,"acquired":true,"shares":396000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four-year period: 1/48th on February 5, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":396000,"derivative":{"exercise_price":10.89,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":396000},"source":{"system":"sec-edgar","filing":"0001209191-24-001055","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919124001055/doc4.xml","form_type":"4"}},{"id":1844034,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to buy Common Stock)","published_at":"2023-06-26T23:35:26.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 22, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":37500,"derivative":{"exercise_price":12.69,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-039810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000120919123039810/doc4.xml","form_type":"4"}},{"id":1963672,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:05:20.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":360000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests over a four-year period: 1/48th on April 6, 2023, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":360000,"derivative":{"exercise_price":4.2,"expiration_date":"2033-03-05","underlying":"Common Stock","underlying_shares":360000},"source":{"system":"sec-edgar","filing":"0001209191-23-017243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017243/doc4.xml","form_type":"4"}},{"id":1963671,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:05:20.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":205000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a four-year period: 1/48th on November 25, 2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":205000,"derivative":{"exercise_price":4.2,"expiration_date":"2032-10-24","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001209191-23-017243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017243/doc4.xml","form_type":"4"}},{"id":1963670,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:05:20.000Z","date":"2023-03-06","kind":"disposition_to_issuer","acquired":false,"shares":205000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a four-year period: 1/48th on November 25, 2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":18.4,"expiration_date":"2032-10-24","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001209191-23-017243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017243/doc4.xml","form_type":"4"}},{"id":1963669,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:05:20.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":467634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":467634,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":467634},"source":{"system":"sec-edgar","filing":"0001209191-23-017243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017243/doc4.xml","form_type":"4"}},{"id":1963668,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:05:20.000Z","date":"2023-03-06","kind":"disposition_to_issuer","acquired":false,"shares":467634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.22,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":467634},"source":{"system":"sec-edgar","filing":"0001209191-23-017243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017243/doc4.xml","form_type":"4"}},{"id":2131147,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Option Grant (right to buy)","published_at":"2022-10-27T16:52:45.000Z","date":"2022-10-25","kind":"grant","acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 6-month period: 1/6th on October 25, 2022, after which 1/6th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":205000,"derivative":{"exercise_price":18.4,"expiration_date":"2032-10-24","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001209191-22-054727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919122054727/doc4.xml","form_type":"4"}},{"id":2222713,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to buy Common Stock)","published_at":"2022-06-23T22:11:04.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total shares on each monthly anniversary, beginning on July 21, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":28700,"derivative":{"exercise_price":16.29,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001209191-22-039050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580111/000120919122039050/doc4.xml","form_type":"4"}},{"id":2272115,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T16:33:15.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service."}],"balance_after":25000,"derivative":{"exercise_price":1.24,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-22-003010","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022003010/edgar.xml","form_type":"4"}},{"id":2542197,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-10-14T16:29:48.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual\nMeeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":7700,"derivative":{"exercise_price":99.83,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001209191-21-060469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564824/000120919121060469/doc4.xml","form_type":"4"}},{"id":2714574,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T20:34:29.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service."}],"balance_after":25000,"derivative":{"exercise_price":23.25,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-21-005312","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021005312/edgar.xml","form_type":"4"}},{"id":2914656,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-01-06T17:32:32.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to one thirty-sixth of the shares on January 21, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":4000,"derivative":{"exercise_price":133.77,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001209191-21-002275","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564824/000120919121002275/doc4.xml","form_type":"4"}},{"id":3135275,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-26T20:52:33.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service."}],"balance_after":25000,"derivative":{"exercise_price":6.22,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-20-006611","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911020006611/edgar.xml","form_type":"4"}},{"id":3310820,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":50105,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":50105},"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3310819,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":36.39,"expiration_date":"2028-05-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3310818,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":93109,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":27.39,"expiration_date":"2027-11-16","underlying":"Common Stock","underlying_shares":93109},"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3310817,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":40883,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.26,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":40883},"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3310816,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":548,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":9.4988,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":548},"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3310815,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":110703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.7649,"expiration_date":"2025-11-06","underlying":"Common Stock","underlying_shares":110703},"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3310814,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2020-01-15T13:29:15.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":104439,"price":60,"value":6266340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003428","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003428/doc4.xml","form_type":"4"}},{"id":3340976,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":false,"shares":14895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":50105,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":14895},"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340975,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":false,"shares":6891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":93109,"derivative":{"exercise_price":27.39,"expiration_date":"2027-11-16","underlying":"Common Stock","underlying_shares":6891},"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340974,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":false,"shares":74117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":40883,"derivative":{"exercise_price":15.26,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":74117},"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340973,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":false,"shares":5715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon the occurrence of certain events."}],"balance_after":548,"derivative":{"exercise_price":9.4988,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":5715},"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340972,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":false,"shares":45726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":110703,"derivative":{"exercise_price":2.7649,"expiration_date":"2025-11-06","underlying":"Common Stock","underlying_shares":45726},"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340971,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"tax_withholding","acquired":false,"shares":88928,"price":59.37,"value":5279655.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the exercise of stock options. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":104439,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340970,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":true,"shares":14895,"price":24.74,"value":368502.3,"ownership":{"direct":true},"balance_after":193367,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340969,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":true,"shares":6891,"price":27.39,"value":188744.49,"ownership":{"direct":true},"balance_after":178472,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340968,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":true,"shares":74117,"price":15.26,"value":1131025.42,"ownership":{"direct":true},"balance_after":171581,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340967,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":true,"shares":5715,"price":9.4988,"value":54285.642,"ownership":{"direct":true},"balance_after":97464,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340966,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"exercise","acquired":true,"shares":45726,"price":2.7649,"value":126427.8174,"ownership":{"direct":true},"balance_after":91749,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3340965,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-16T18:03:15.000Z","date":"2019-12-12","kind":"tax_withholding","acquired":false,"shares":8681,"price":59.37,"value":515390.97,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On December 10, 2019, the Compensation Committee of the Issuer's Board of Directors approved the accelerated vesting and settlement of restricted stock units granted on February 6, 2019 in order to mitigate the potential adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":46023,"source":{"system":"sec-edgar","filing":"0001209191-19-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060728/doc4.xml","form_type":"4"}},{"id":3348157,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-12-09T17:15:52.000Z","date":"2019-12-05","kind":"tax_withholding","acquired":false,"shares":505,"price":59.21,"value":29901.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":54704,"source":{"system":"sec-edgar","filing":"0001209191-19-059739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119059739/doc4.xml","form_type":"4"}},{"id":3419589,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-09-09T16:04:30.000Z","date":"2019-09-05","kind":"tax_withholding","acquired":false,"shares":505,"price":31.02,"value":15665.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":55209,"source":{"system":"sec-edgar","filing":"0001209191-19-048876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119048876/doc4.xml","form_type":"4"}},{"id":3497265,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-06-07T16:41:15.000Z","date":"2019-06-05","kind":"tax_withholding","acquired":false,"shares":1009,"price":37.31,"value":37645.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":55714,"source":{"system":"sec-edgar","filing":"0001209191-19-035584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119035584/doc4.xml","form_type":"4"}},{"id":3572093,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-01T18:01:04.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in equal quarterly installments over the twelve quarters following the grant date."}],"balance_after":50000,"derivative":{"exercise_price":18.1,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-19-019036","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465919019036/a4.xml","form_type":"4"}},{"id":3668142,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T17:20:59.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":65000,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-19-008664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008664/doc4.xml","form_type":"4"}},{"id":3668141,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-02-08T17:20:59.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":23333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration.  The RSUs will vest as to 2/16ths of the award on June 5, 2019, and then 1/16th of the RSUs will vest on each of September 5, December 5, March 5 and June 5 thereafter until the RSUs are fully vested, subject to the Reporting Person's provision of services to the issuer on each vesting date.  Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting."}],"balance_after":56723,"source":{"system":"sec-edgar","filing":"0001209191-19-008664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008664/doc4.xml","form_type":"4"}},{"id":3686913,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-25T19:28:58.000Z","date":"2019-01-24","kind":"exercise","acquired":false,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":156429,"derivative":{"exercise_price":2.7649,"expiration_date":"2025-11-06","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001209191-19-005437","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119005437/doc4.xml","form_type":"4"}},{"id":3686912,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2019-01-25T19:28:58.000Z","date":"2019-01-24","kind":"exercise","acquired":true,"shares":8300,"price":2.7649,"value":22948.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired in connection with the exercise of stock options described in Table II."}],"balance_after":33390,"source":{"system":"sec-edgar","filing":"0001209191-19-005437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119005437/doc4.xml","form_type":"4"}},{"id":3908463,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-04T16:48:53.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":5090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":164729,"derivative":{"exercise_price":2.7649,"expiration_date":"2025-11-06","underlying":"Common Stock","underlying_shares":5090},"source":{"system":"sec-edgar","filing":"0001209191-18-035174","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118035174/doc4.xml","form_type":"4"}},{"id":3908462,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2018-06-04T16:48:53.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":5090,"price":2.7649,"value":14073.341,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired in connection with the exercise of stock options described in Table II."}],"balance_after":25090,"source":{"system":"sec-edgar","filing":"0001209191-18-035174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118035174/doc4.xml","form_type":"4"}},{"id":3942623,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (right to buy)","published_at":"2018-05-08T08:08:45.000Z","date":"2018-05-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning June 2, 2018, with 100% of the total shares vested and exercisable on May 2, 2022, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":36.39,"expiration_date":"2028-05-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-028492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118028492/doc4.xml","form_type":"4"}},{"id":4158256,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, COO"}}],"security":"Stock Option (right to buy)","published_at":"2017-11-17T17:04:48.000Z","date":"2017-11-16","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":27.39,"expiration_date":"2027-11-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-17-061538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117061538/doc4.xml","form_type":"4"}},{"id":4298275,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, COO"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-01T16:31:42.000Z","date":"2017-05-31","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":169819,"derivative":{"exercise_price":2.76,"expiration_date":"2025-11-06","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-036792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117036792/doc4.xml","form_type":"4"}},{"id":4298274,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, COO"}}],"security":"Common Stock","published_at":"2017-06-01T16:31:42.000Z","date":"2017-05-31","kind":"exercise","acquired":true,"shares":20000,"price":2.76,"value":55200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired in connection with the exercise of stock options described in Table II."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-17-036792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117036792/doc4.xml","form_type":"4"}},{"id":4479280,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":35603,"kind":"person","name":"Holles Natalie C.","position":1,"cik":"0001580111","reported_name":"Holles Natalie C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, COO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-27T18:06:57.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":115000,"derivative":{"exercise_price":15.26,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-17-005995","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117005995/doc4.xml","form_type":"4"}}]}